Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.
Hejna M, Raderer M, Zacherl J, Ba-Ssalamah A, Püspök A, Schmidinger M, Pluschnig U, Brodowicz T, Zielinski CC. Hejna M, et al. Among authors: pluschnig u. Anticancer Drugs. 2008 Jun;19(5):535-9. doi: 10.1097/CAD.0b013e3282fb178a. Anticancer Drugs. 2008. PMID: 18418220 Clinical Trial.
Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna.
Bojic M, Pluschnig U, Zacherl J, Thallinger CM, Ba-Ssalamah A, Maresch J, Datler P, Schoppmann SF, Hejna M. Bojic M, et al. Among authors: pluschnig u. Anticancer Res. 2011 Jun;31(6):2379-82. Anticancer Res. 2011. PMID: 21737668
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Ilhan-Mutlu A, Preusser M, Schoppmann SF, Asari R, Ba-Ssalamah A, Schwameis K, Pluschnig U, Birner P, Püspök A, Zacherl J, Hejna M. Ilhan-Mutlu A, et al. Among authors: pluschnig u. Anticancer Res. 2013 Aug;33(8):3455-9. Anticancer Res. 2013. PMID: 23898119
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG. Wenzel C, et al. Among authors: pluschnig u. Cancer Chemother Pharmacol. 2002 Aug;50(2):155-9. doi: 10.1007/s00280-002-0476-9. Epub 2002 Jun 7. Cancer Chemother Pharmacol. 2002. PMID: 12172982 Clinical Trial.
64 results